Cite
MLA Citation
Toby A. Eyre et al.. “A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.” Hematological oncology, vol. 37, no. 4, 2019, pp. 352–359. http://access.bl.uk/ark:/81055/vdc_100094615622.0x000049